US Patent Issued to Regeneron Pharmaceuticals on Sept. 23 for "Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies" (New York Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,421,317, issued on Sept. 23, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies" was invented by Haruka Okamoto (Ardsley, N.Y.) and Jee H. Kim (Ardsley, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to antibodies or antigen-binding fragments thereof that bind specifically to the glucagon-like peptide 1 receptor (GLP1R) protein, and methods of use thereof. In various embodiments, the antibodies or antigen-binding fragments thereof are fully human antibodies that bind to GLP1R. In some embodiments, the antibodi...